UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Frontiers in immunology, 2022-01, Vol.13, p.807271-807271

2022

Link zum Volltext

Verfügbarkeit prüfen

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Molecular cancer, 2024-02, Vol.23 (1), p.38-38, Article 38

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.1-149, Article 149

2022

Link zum Volltext

Verfügbarkeit prüfen

Nonapoptotic functions of Fas/CD95 in the immune response

The FEBS journal, 2018-03, Vol.285 (5), p.809-827

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

Experimental hematology & oncology, 2022-12, Vol.11 (1), p.104-104, Article 104

2022

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Clinical cancer research, 2021-04, Vol.27 (8), p.2139-2147

2021

Link zum Volltext

Verfügbarkeit prüfen

Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study

Biomarker research, 2024-01, Vol.12 (1), p.3-3, Article 3

2024

Link zum Volltext

Verfügbarkeit prüfen

The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses

Journal of cellular physiology, 2012-01, Vol.227 (1), p.59-69

2012

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

European journal of cancer (1990), 2022-02, Vol.162, p.161-169

2022

Link zum Volltext

Verfügbarkeit prüfen

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Clinical cancer research, 2022-05, Vol.28 (9), p.1765-1772

2022

Link zum Volltext

Verfügbarkeit prüfen

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer

Clinical cancer research, 2023-12, Vol.29 (23), p.4883

2023

Link zum Volltext

Verfügbarkeit prüfen

CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

iScience, 2021-11, Vol.24 (11), p.103348-103348, Article 103348

2021

Link zum Volltext

Verfügbarkeit prüfen

TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2024-02, Vol.30 (4), p.779

2024

Link zum Volltext

Verfügbarkeit prüfen

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e003890

2022

Link zum Volltext

Verfügbarkeit prüfen

MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells

Carcinogenesis (New York), 2013-01, Vol.34 (1), p.38-47

2013

Link zum Volltext

Verfügbarkeit prüfen

MEK1/2 Overactivation Can Promote Growth Arrest by Mediating ERK1/2-Dependent Phosphorylation of p70S6K

Journal of cellular physiology, 2014-07, Vol.229 (7), p.903-915

2014

Link zum Volltext

Verfügbarkeit prüfen

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

iScience, 2021-12, Vol.24 (12), p.103538-103538, Article 103538

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.1-157, Article 157

2022

Link zum Volltext

Verfügbarkeit prüfen

Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction

Bioorganic & medicinal chemistry letters, 2019-11, Vol.29 (21), p.126669, Article 126669

2019

Link zum Volltext

Verfügbarkeit prüfen

Signaling by the tyrosine kinase Yes promotes liver cancer development

Science signaling, 2022-01, Vol.15 (717), p.eabj4743

2022

Link zum Volltext

Verfügbarkeit prüfen

HIV protease inhibitors and autoimmunity: An odd, but promising idea

Autoimmunity reviews, 2019-10, Vol.18 (10), p.102370, Article 102370

2019

Link zum Volltext

Verfügbarkeit prüfen

CD95/Fas and metastatic disease: What does not kill you makes you stronger

Seminars in cancer biology, 2020-02, Vol.60, p.121-131

2020

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of peptidomimetics and chemo-biological tools for CD95/PLC gamma 1 interaction analysis

Bioorganic & medicinal chemistry letters, 2019-08, Vol.29 (16), p.2094-2099

2019

Link zum Volltext

Verfügbarkeit prüfen

Disrupting the CD95-PLCγ1 interaction prevents Th17-driven inflammation

Nature chemical biology, 2018-12, Vol.14 (12), p.1079

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

Nonapoptotic functions of Fas/CD95 in the immune response

Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study

The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells

TROP2 Is Associated with Primary Resistance to Immune Checkpoint Inhibition in Patients with Advanced Non-Small Cell Lung Cancer

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells

MEK1/2 Overactivation Can Promote Growth Arrest by Mediating ERK1/2-Dependent Phosphorylation of p70S6K

CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study

Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction

Signaling by the tyrosine kinase Yes promotes liver cancer development

HIV protease inhibitors and autoimmunity: An odd, but promising idea

CD95/Fas and metastatic disease: What does not kill you makes you stronger

Synthesis of peptidomimetics and chemo-biological tools for CD95/PLC gamma 1 interaction analysis

Disrupting the CD95-PLCγ1 interaction prevents Th17-driven inflammation

Suchergebnisse filtern